Elan and Transition Therapeutics has presented phase 1 data, which demonstrated that treatment with ELND005 (scyllo-inositol) has achieved desired concentrations in human brain tissue and cerebrospinal fluid.
ELND005 is an orally-administered drug candidate in phase 2 trials, for the treatment of mild-to-moderate Alzheimer’s disease.
Preclinical data also showed that ELND005 administration is associated with preservation of choline acetyltransferase.
Carlos Paya, president of Elan, said: Achieving a clinically beneficial concentration of drug in brain tissue and cerebrospinal fluid has presented a significant hurdle to other drugs investigated to treat Alzheimer’s Disease, so this is an important proof of concept for us.
We look forward to completing and reporting results from our ongoing Phase 2 study of ELND005 in patients with mild to moderate Alzheimer’s disease, which completed enrollment in October 2008, he added.